Zhejiang Jiuzhou Pharmaceutical Co., Ltd Share Price

Equities

603456

CNE100001W36

Pharmaceuticals

End-of-day quote Shanghai S.E. 03:30:00 26/04/2024 am IST 5-day change 1st Jan Change
15.6 CNY +3.24% Intraday chart for Zhejiang Jiuzhou Pharmaceutical Co., Ltd +5.62% -35.56%

Financials

Sales 2024 * 6.29B 869M 72.43B Sales 2025 * 7.25B 1B 83.44B Capitalization 14.03B 1.94B 161B
Net income 2024 * 1.26B 174M 14.49B Net income 2025 * 1.59B 219M 18.28B EV / Sales 2024 * 2.23 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.94 x
P/E ratio 2024 *
11.2 x
P/E ratio 2025 *
8.84 x
Employees 4,877
Yield 2024 *
3.11%
Yield 2025 *
3.62%
Free-Float 57.03%
More Fundamentals * Assessed data
Dynamic Chart
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jiuzhou Pharmaceutical Gets Nod to Market Sitagliptin Metformin Tablets; Shares Drop 4% MT
Ruibo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 15 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Tranche Update on Zhejiang Jiuzhou Pharmaceutical Co., Ltd's Equity Buyback Plan announced on January 5, 2024. CI
Jiuzhou Pharma to Build $42 Million CRO Platform in Japan MT
Zhejiang Jiuzhou Pharmaceutical Co., Ltd announces an Equity Buyback for CNY 100 million worth of its shares. CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd authorizes a Buyback Plan. CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it has received CNY 50 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it has received CNY 100 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 50 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it expects to receive CNY 100 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Ruibo Pharmaceutical Technology Co., Ltd. announced that it has received CNY 20 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd CI
More news
1 day+3.24%
1 week+5.62%
Current month-12.51%
1 month-13.29%
3 months-19.96%
6 months-41.22%
Current year-35.56%
More quotes
1 week
14.56
Extreme 14.56
15.68
1 month
14.56
Extreme 14.56
18.17
Current year
14.56
Extreme 14.56
24.28
1 year
14.56
Extreme 14.56
32.39
3 years
14.56
Extreme 14.56
63.00
5 years
7.27
Extreme 7.27
63.00
10 years
5.14
Extreme 5.1444
63.00
More quotes
Managers TitleAgeSince
President 53 06/18/06
President 49 06/18/06
Director of Finance/CFO 44 18/21/18
Members of the board TitleAgeSince
Chairman 56 18/14/18
Director/Board Member 51 18/14/18
Director/Board Member 72 18/14/18
More insiders
Date Price Change Volume
26/24/26 15.6 +3.24% 23,260,780
25/24/25 15.11 +2.65% 26,122,290
24/24/24 14.72 -1.47% 16,445,000
23/24/23 14.94 +0.67% 17,483,820
22/24/22 14.84 +0.47% 16,338,600

End-of-day quote Shanghai S.E., April 26, 2024

More quotes
Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.6 CNY
Average target price
23.2 CNY
Spread / Average Target
+48.73%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603456 Stock